**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1.-37. (Cancelled)

38. (Currently Amended) A polynucleotide encoding a fusion protein which is stable in a cell, said fusion protein comprising:

(a) a first (poly)peptide which is unstable in a cell**, wherein said first (poly)peptide comprises at least one of an epitope, a functional domain of a protein, a structural domain of a protein, a mutated variant of a protein or a truncated variant of a protein, the protein being derived from a pathogen**; and

(b) a second (poly)peptide, which is ~~a viral T antigen~~ **SV40 large T-antigen** carrying at least one of an internal deletion or a C-terminal deletion and which co-precipitates a chaperone, wherein said chaperone ~~is hsp73~~ **belongs to the family of heat shock protein (hsp)70 chaperone**.

39. (Cancelled)

40. (Previously Presented) The polynucleotide of claim 38, wherein at least one of the function or the structure of the N-terminal J domain of said viral T antigen is maintained.

41. – 43. (Cancelled)

44. (Currently Amended) The polynucleotide of claim ~~43~~ **38**, wherein about 300 C-terminal amino acids of said SV40 large T antigen are deleted.

45. (Currently Amended) The polynucleotide of claim ~~43~~ **38**, wherein said SV40 large T antigen contains amino acids 1 to 272.

46. (Currently Amended) The polynucleotide of claim ~~43~~ **38**, wherein the internal deletion comprises at least part of the nuclear localisation signal.

47. (Previously Presented) The polynucleotide of claim 46, wherein amino acids 110 to 152 are deleted.

48. (Previously Presented) The polynucleotide of claim 38 further encoding a tag.

49. (Previously Presented) The polynucleotide of claim 38, wherein said first and second (poly)peptide are linked via a protease cleavage site.

50. (Previously Presented) A vector comprising the polynucleotide of claim 38.

51. (Previously Presented) A host cell comprising the polynucleotide of claim 38 or a vector comprising said polynucleotide.

52. (Previously Presented) A method for the production of a fusion protein, said method comprising:

(a) culturing the host cell comprising the polynucleotide of claim 38 under conditions that allow the synthesis of said fusion protein; and

(b) recovering said fusion protein from the culture.

53. (Previously Presented) The method of claim 52 further comprising the step of separating said fusion protein from complexed chaperones.

54. (Cancelled)

55. (Previously Presented) A method for the production of a first (poly)peptide which is unstable in a cell, said method comprising:

(a) culturing the host cell comprising the polynucleotide of claim 38 under conditions that allow the synthesis of a fusion protein, wherein said first and second (poly)peptide are linked via a protease cleavage site;

(b) recovering said fusion protein from the culture; and

(c) separating said second (poly)peptide from said fusion protein by proteolytic cleavage.

56. (Previously Presented) A method for the production of a complex comprising a fusion protein and a chaperone, said method comprising:

(a) culturing the host cell comprising the polynucleotide of claim 38 under conditions that allow complex formation of said fusion protein with said chaperone; and

(b) recovering said complex from the culture.

57. – 58. (Cancelled)

59. (Previously Presented) A kit comprising at least one of:

(a) the polynucleotide of claim 38;

(b) a vector comprising said polynucleotide; and

(c) a host cell comprising said polynucleotide or a vector comprising said polynucleotide.

60. – 66. (Cancelled)